Evidence of Histone Modification Affecting the ARID1A Expression in Colorectal Cancer Cell lines
Gastroenterology and Hepatology from Bed to Bench,
Aim: This study aimed to focus on the role of histone deacetylation in reduced ARID1A expression in colorectal cancer cell lines.
Background: ARID1A, a subunit of the switch/sucrose nonfermentable chromatin remodeling complex, has emerged as a bona fide tumor suppressor and is frequently down regulated and inactivated in multiple human cancers. Epigenetic modifications have an important role in dysregulation of gene expression in cancer. DNA methylation has been reported as an important regulator of ARID1A expression in colorectal cancer cell lines, however, histone modification role in ARID1A suppression in colorectal cancer remains unclear. Methods: The expression levels of ARID1A mRNA were determined using real-time quantitative PCR in colorectal cancer cell lines including HCT116, SW48, HT29, SW742, LS180 and SW480. In order to evaluate the effect of histone deacetylation on ARID1A expression, all cell lines were treated by trichostatin A (TSA), a histone deacetylase inhibitor. SPSS software (Version 23) and GraphPad Prism (Version 6.01) were applied for data analysis using the one-way ANOVA, followed by Tukey’s multiple comparison tests. Results: Treatment of colorectal cancer cell lines with TSA increased ARID1A expression in a cell line-dependent manner, suggesting that histone deacetylation is at least one factor, contributing to ARID1A downregulation in colorectal cancer. Conclusion: Histone deacetylases inhibitors might provide a strategy to restore ARID1A expression, and may bring benefits to the colorectal cancer patients with a broader range of genetic backgrounds.
- ARID1A, Histone acetylation, Colorectal cancer, Epigenetics
How to Cite
2. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero‐Luna G, et al. Cancer statistics for hispanics/latinos, 2018. CA Cancer J. Clin 2018;68(6):425-45. https://acsjournals.onlinelibrary.wiley.com/doi/full/10.3322/caac.21494
3. Lu Y-W, Zhang H-F, Liang R, Xie Z-R, Luo H-Y, Zeng Y-J, et al. Colorectal cancer genetic heterogeneity delineated by multi-region sequencing. PloS one 2016;11(3):e0152673. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0152673
4. Nguyen HT, Duong HQ. The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy. Oncol Lett 2018;16(1):9-18.
5. Mathur R, Alver BH, San Roman AK, Wilson BG, Wang X, Agoston AT, et al. ARID1A loss impairs enhancer-mediated gene regulation and drives colon cancer in mice. Nat Genet 2017;49(2):296. https://www.spandidos-publications.com/10.3892/ol.2018.8679?text=abstract
6. Dallas PB, Cheney IW, Liao D-W, Bowrin V, Byam W, Pacchione S, et al. p300/CREB binding protein-related protein p270 is a component of mammalian SWI/SNF complexes. Mol Cell Biol 1998;18(6):3596-603. https://mcb.asm.org/content/18/6/3596.short
7. Oike T, Ogiwara H, Nakano T, Yokota J, Kohno T. Inactivating mutations in SWI/SNF chromatin remodeling genes in human cancer. Jpn J Clin Oncol 2013;43(9):849-55. https://academic.oup.com/jjco/article/43/9/849/859060
8. Jones S, Li M, Parsons DW, Zhang X, Wesseling J, Kristel P, et al. Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat 2012;33(1):100-3. https://onlinelibrary.wiley.com/doi/full/10.1002/humu.21633
9. Chou A, Toon CW, Clarkson A, Sioson L, Houang M, Watson N, et al. Loss of ARID1A expression in colorectal carcinoma is strongly associated with mismatch repair deficiency. Hum Pathol 2014;45(8):1697-703.
10. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet 2011;43(12):1219. https://www.nature.com/articles/ng.982
11. Pavlidou EN, Balis V. Diagnostic significance and prognostic role of the ARID1A gene in cancer outcomes. World Acad Sci J 2020;2(2):49-64. https://www.spandidos-publications.com/10.3892/wasj.2020.37
12. Yang L, Wei S, Zhao R, Wu Y, Qiu H, Xiong H. Loss of ARID1A expression predicts poor survival prognosis in gastric cancer: a systematic meta-analysis from 14 studies. Sci Rep 2016;6(1):1-8. https://www.nature.com/articles/srep28919
13. Katagiri A, Nakayama K, Rahman MT, Rahman M, Katagiri H, Nakayama N, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol 2012;25(2):282-8. https://www.nature.com/articles/modpathol2011161/
14. Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330. https://www.nature.com/articles/nature11252
15. Cajuso T, Hänninen UA, Kondelin J, Gylfe AE, Tanskanen T, Katainen R, et al. Exome sequencing reveals frequent inactivating mutations in ARID1A, ARID1B, ARID2 and ARID4A in microsatellite unstable colorectal cancer. Int J Cancer 2014;135(3):611-23. https://onlinelibrary.wiley.com/doi/full/10.1002/ijc.28705
16. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6(269):pl1-pl. https://stke.sciencemag.org/content/6/269/pl1.short
17. Kishida Y, Oishi T, Sugino T, Shiomi A, Urakami K, Kusuhara M, et al. Associations between loss of ARID1A expression and Clinicopathologic and genetic variables in T1 early colorectal Cancer. Am J Clin Pathol 2019;152(4):463-70. https://academic.oup.com/ajcp/article-abstract/152/4/463/5527063
18. Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, et al. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS One 2013;8(1):e53931.
19. Shain AH, Giacomini CP, Matsukuma K, Karikari CA, Bashyam MD, Hidalgo M, et al. Convergent structural alterations define SWItch/Sucrose NonFermentable (SWI/SNF) chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. Proc Natl Acad Sci 2012;109(5):E252-E9. https://europepmc.org/article/pmc/pmc3277150
20. Erfani M, Hosseini SV, Mokhtari M, Zamani M, Tahmasebi K, Alizadeh Naini M, et al. Altered ARID1A expression in colorectal cancer. BMC cancer 2020;20:1-13. https://bmccancer.biomedcentral.com/articles/10.1186/s12885-020-6706-x
21. Wei X-L, Wang D-S, Xi S-Y, Wu W-J, Chen D-L, Zeng Z-L, et al. Clinicopathologic and prognostic relevance of ARID1A protein loss in colorectal cancer. World J Gastroenterol 2014;20(48):18404. https://europepmc.org/article/pmc/4277979
22. Lu Y, Chan Y-T, Tan H-Y, Li S, Wang N, Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy. Mol Cancer 2020;19:1-16. https://molecular-cancer.biomedcentral.com/articles/10.1186/s12943-020-01197-3
23. Sen M, Wang X, Hamdan FH, Rapp J, Eggert J, Kosinsky RL, et al. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells. Clin Epigenetics 2019;11(1):1-16.
24. Lee SY, Kim D-W, Lee HS, Ihn MH, Oh H-K, Park DJ, et al. Loss of AT-rich interactive domain 1A expression in gastrointestinal malignancies. Oncology 2015;88(4):234-40. https://www.karger.com/Article/Abstract/369140
25. Aso T, Uozaki H, Morita S, Kumagai A, Watanabe M. Loss of ARID1A, ARID1B, and ARID2 expression during progression of gastric cancer. Anticancer Res 2015;35(12):6819-27.
26. Baxter E, Windloch K, Gannon F, Lee JS. Epigenetic regulation in cancer progression. Cell Biosci 2014;4(1):1-11. http://ar.iiarjournals.org/content/35/12/6819.short
27. Mariadason JM. HDACs and HDAC inhibitors in colon cancer. Epigenetics 2008;3(1):28-37. https://www.tandfonline.com/doi/abs/10.4161/epi.3.1.5736
- Abstract Viewed: 0 times
- pdf Downloaded: 0 times